1
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Condition(s):Non-small Cell Lung CancerLast Updated:July 7, 2020Recruiting
Trametinib: 225 Clinical Trials, Page 1 of 23
Hide Studies Not Open or Pending
2
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Condition(s):Juvenile Myelomonocytic Leukemia; Neurofibromatosis Type 1Last Updated:April 14, 2021Recruiting
3
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
Condition(s):Low-grade Glioma; Plexiform Neurofibroma; Central Nervous System GliomaLast Updated:March 22, 2021Recruiting
4
Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
Condition(s):Non-small Cell Lung CancerLast Updated:December 3, 2019Terminated
5
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
Condition(s):Stage IV Melanoma; Stage III MelanomaLast Updated:December 17, 2020Recruiting
6
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
Condition(s):Malignant Neoplasms of Digestive Organs; Colorectal Cancer; Colon CancerLast Updated:April 2, 2020Active, not recruiting
7
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
Condition(s):Bronchial NeoplasmsLast Updated:July 15, 2019Recruiting
8
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
Condition(s):Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell MyelomaLast Updated:March 12, 2021Active, not recruiting
9
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
Condition(s):Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell MyelomaLast Updated:April 2, 2021Active, not recruiting
10
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
Condition(s):Metastatic Pancreatic Carcinoma; Stage II Pancreatic Cancer; Stage IIA Pancreatic Cancer; Stage IIB Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Unresectable Pancreatic CarcinomaLast Updated:November 13, 2020Recruiting